Article Text

Download PDFPDF
CASE REPORT
Multidrug-resistant tuberculosis in rural China: lack of public awareness, unaffordable costs and poor clinical management
  1. Yu Chen1,
  2. Yanping Zhao2
  1. 1Department of Tuberculosis, Shenyang Tenth People’s Hospital and Shenyang Chest Hospital, Shenyang, China
  2. 2School of Public Health, The University of Hong Kong, Hong Kong, China
  1. Correspondence to Dr Yanping Zhao, zhaohelen{at}connect.hku.hk

Summary

China has the second highest global incidence and prevalence of multidrug-resistant tuberculosis (MDR-TB). We describe here the life experience of a rural Chinese farmer with complicated and aggressive TB. It is unclear if this patient contracted MDR-TB initially or developed MDR-TB during treatment because the initial laboratory results are dubious. The lack of public awareness of TB in rural China fuelled by a belief in toxicity of TB treatment, as mentioned by his brother, caused the patient to stop his TB treatment repeatedly long before completion. The cost of MDR-TB treatment in China is unaffordable for most Chinese, especially those in rural areas. He paid about ¥300 000 (almost US$50 000) for his TB treatment. He was discharged early twice for ‘financial difficulties’. This case highlights excessive costs, lack of public awareness, poor patient education, inadequate follow-up, lack of coordination between clinical services and the importance of treatment adherence.

  • global health
  • healthcare improvement and patient safety
  • infectious diseases
  • tb and other respiratory infections

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors YC and YZ take responsibility for planning, conducting and reporting the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.